Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “MEDROXYPROGESTERONE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,621 records · Page 90Linked to original sources
PubMed1982

[Combined drug/hormone therapy in metastatic breast cancer with vincristine, adriamycin, cyclophosphamide and high dose medroxyprogesterone acetate--VAC-MAP. Preliminary results of a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].

In a study of the AIO 67 patients with metastatic breast cancer were treated with VAC-MAP--a combination of chemo- and hormonal therapy consisting of vincristine 1 mg/m2 day 1, i.v.; adriamycin 40 mg/m2 day 1, i.v.; cyclophosphamide 200 mg/m2 day, 3-6, p.o. and medroxyprogesteroneacetate 1500 mg daily (day 1-42), 500 mg daily from day 42 until relapse. At present, 50 patients are evaluable. Remission rates of all patients correspond with those described in the literature for VAC, i.e. 58%. In CMF-resistant cases remissions were obtained in 50% of the patients and even 78.6% in hormone receptor positive tumors. Only 2 patients did not respond to the therapy. It appears that with a maintenance therapy of 500 mg MAP daily remission duration cannot be prolonged, apparently due to too low a dosage. MAP should improve the subjective tolerance of chemotherapy and bone marrow tolerance towards cytostatic drugs.

Adult↗